Ditchcarbon
  • Contact
  1. Organizations
  2. Argenx
Public Profile
Pharmaceutical Preparation Manufacturing
NL
updated a month ago

Argenx

Company website

Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.

DitchCarbon Score

How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

41

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Argenx's score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Argenx's reported carbon emissions

In 2024, Argenx reported total carbon emissions of approximately 231,769,000 kg CO2e. This figure includes 3,788,000 kg CO2e from Scope 1 emissions, 534,000 kg CO2e from Scope 2 emissions (market-based), and a significant 227,447,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (about 183,781,000 kg CO2e) and business travel (approximately 13,340,000 kg CO2e). In 2023, Argenx's total emissions were higher, at about 433,353,000 kg CO2e, with Scope 1 emissions at 378,000 kg CO2e, Scope 2 emissions at 189,000 kg CO2e (market-based), and Scope 3 emissions reaching approximately 432,786,000 kg CO2e. The largest contributors to Scope 3 emissions in 2023 were also purchased goods and services (around 378,956,000 kg CO2e) and capital goods (approximately 28,054,000 kg CO2e). Despite these substantial emissions figures, Argenx has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The company does not appear to have cascaded any emissions data from a parent organization, and all reported figures are derived directly from Argenx SE. Overall, while Argenx has made strides in transparency regarding its emissions, further commitments to reduction targets and initiatives would enhance its climate strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20232024
Scope 1
378,000
0,000,000
Scope 2
189,000
000,000
Scope 3
432,786,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Argenx's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Argenx is in NL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Argenx is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

STADA Arzneimittel Aktiengesellschaft

DE
•
Pharmaceutical Preparation Manufacturing
Updated 14 minutes ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Ablynx NV

BE
•
Pharmaceutical Preparation Manufacturing
Updated 19 days ago

Molecular Partners AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Zealand Pharma A/S

DK
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251008.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy